Source: Annual Congress 2012 - COPD exacerbation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Pertseva, K. Gashynova, O. Bratus, N. Petrik (Dnipropetrovs, Ukraine). COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level. Eur Respir J 2012; 40: Suppl. 56, 4825

Member's Comments

No comment yet.

Related content which might interest you: COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts) Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006 Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples Source: Eur Respir J 2005; 26: Suppl. 49, 595s Year: 2005 The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010 Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts) Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002 Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD) Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE) Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015